Revolution Medicines to Update on RMC-6236 Pancreatic Cancer Program July 15, 2024

REDWOOD CITY, Calif., July 08, 2024-- Revolution Medicines, Inc. (Nasdaq: RVMD), a company focusing on oncology and developing targeted therapies for RAS-addicted cancers, has announced an upcoming investor webcast. This event will provide updates on the RMC-6236 clinical development program for pancreatic ductal adenocarcinoma (PDAC). The webcast is scheduled for Monday, July 15, 2024, at 8:00 a.m. Eastern Time.

During the webcast, Revolution Medicines' management team will be joined by Brian M. Wolpin, M.D., M.P.H., a professor of medicine at Harvard Medical School. Dr. Wolpin also serves as the director of the Gastrointestinal Cancer Center and holds the Robert T. & Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute.

The live webcast can be accessed through the “Events & Presentations” section on Revolution Medicines’ website. For those who cannot attend the live session, a replay will be available on the same webpage for at least 14 days post-event.

Revolution Medicines is an innovative company in the field of oncology, focusing on the development of novel targeted therapies aimed at RAS-addicted cancers. These cancers are driven by mutations in the RAS gene, which is a critical component in cell signaling pathways that control cell growth and survival.

The company’s research and development pipeline includes a variety of RAS(ON) inhibitors, which are designed to target different oncogenic variants of RAS proteins. Among these, RMC-6236, a multi-selective RAS(ON) inhibitor, is notable for its clinical development in targeting multiple RAS mutations. Other key inhibitors in clinical development include RMC-6291, which targets the G12C mutation, and RMC-9805, which is specific to the G12D mutation.

Further development plans involve RAS(ON) mutant-selective inhibitors such as RMC-5127 for the G12V mutation, RMC-0708 targeting the Q61H mutation, and RMC-8839 for the G13C mutation. Revolution Medicines also explores combination treatment strategies with RAS companion inhibitors like RMC-4630, which targets SHP2, and RMC-5552, which inhibits mTORC1/4EBP1.

These innovative therapies are part of Revolution Medicines’ broader strategy to develop effective treatments for various forms of RAS-driven cancers, offering new hope for patients with these challenging malignancies. Revolution Medicines continues to leverage its expertise in RAS biology and drug discovery to advance its pipeline and deliver new oncology therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!